(redirected from Pre-exposure prophylaxis)
Also found in: Dictionary, Thesaurus, Medical, Acronyms, Encyclopedia, Wikipedia.
Related to Pre-exposure prophylaxis: Truvada, Post-exposure prophylaxis
See: deterrence
References in periodicals archive ?
FEM-PrEP: Adherence patterns and factors associated with adherence to a daily oral study product for pre-exposure prophylaxis.
Emtricitabine-tenofovir concentrations and pre-exposure prophylaxis efficacy in men who have sex with men.
12) In a study involving only women receiving pre-exposure prophylaxis (PrEP), the only difference found between the patients using TDF/FTC orally compared to the use of 1% TDF gel was an increase in creatinine levels (1.
The FEM-PrEP clinical trial tested TDF/FTC as pre-exposure prophylaxis among HIV-negative women at risk of HIV infection in four sites in sub-Saharan Africa.
Fauci was referring to a range of HIV prevention options that have been proven to work effectively such as: HIV testing and counselling, treatment as prevention, voluntary medical male circumcision (VMMC), treatment of STIs, rectal and vaginal microbicides (both are currently under research), prevention or treatment of drug and alcohol use, provision of clean needles and syringes, education, behaviour modification, male and female condoms, blood supply screening, antiretroviral drugs for prevention of mother to child transmission of HIV (PMTCT), Post-Exposure Prophylaxis (PEP), and Pre-Exposure Prophylaxis (PrEP).
Moving HIV pre-exposure prophylaxis into clinical settings: lessons from buprenorphine.
LOS ANGELES -- Citing another failed clinical trial in women of the use of Gilead Sciences' AIDS drug Truvada as a form of Pre-exposure Prophylaxis (PrEP) to prevent HIV infection, AIDS Healthcare Foundation (AHF), the nation's largest HIV/AIDS nonprofit medical provider, today urged the Food and Drug Administration (FDA) to remove this indication for use by women citing insufficient data demonstrating the drug's safety and efficacy.
Bone mineral density in HIV-negative men participating in a Tenofovir pre-exposure prophylaxis randomized clinical trial in San Francisco.
Grant is the protocol chair for the Pre-Exposure Prophylaxis Initiative (iPrEx) trial, (1) the first placebo-controlled trial to demonstrate partial protection from HIV infection with oral preexposure prophylaxis (PrEP).
16) Currently, there are no available options for pre-exposure prophylaxis for HCV or HIV.
The United States Food and Drug Administration (FDA) has registered Truvada for pre-exposure prophylaxis for men and women.
Other important interventions include medical male circumcision, which offers a highly effective and durable way to protect heterosexual men from HIV infection; and potentially, pre-exposure prophylaxis with antiretroviral medications, which have shown promise in reducing an individual's risk of acquiring HIV infection.